IGM Biosciences, Inc. 1K0.F Stock
IGM Biosciences, Inc. Price Chart
IGM Biosciences, Inc. 1K0.F Financial and Trading Overview
IGM Biosciences, Inc. stock price | 6.15 EUR |
Previous Close | 9.05 EUR |
Open | 9.1 EUR |
Bid | 9.15 EUR x N/A |
Ask | 9.25 EUR x N/A |
Day's Range | 9.1 - 9.1 EUR |
52 Week Range | 8.9 - 26.6 EUR |
Volume | 80 EUR |
Avg. Volume | 15 EUR |
Market Cap | 390.99M EUR |
Beta (5Y Monthly) | -0.241701 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.93 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 103 EUR |
1K0.F Valuation Measures
Enterprise Value | 58.82M EUR |
Trailing P/E | N/A |
Forward P/E | -1.4536741 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 245.74805 |
Price/Book (mrq) | 1.6414142 |
Enterprise Value/Revenue | 36.971 |
Enterprise Value/EBITDA | -0.253 |
Trading Information
IGM Biosciences, Inc. Stock Price History
Beta (5Y Monthly) | -0.241701 |
52-Week Change | -27.90% |
S&P500 52-Week Change | 20.43% |
52 Week High | 26.6 EUR |
52 Week Low | 8.9 EUR |
50-Day Moving Average | 11.09 EUR |
200-Day Moving Average | 17.46 EUR |
1K0.F Share Statistics
Avg. Volume (3 month) | 15 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 29.51M |
Float | 9.28M |
Short Ratio | N/A |
% Held by Insiders | 38.12% |
% Held by Institutions | 61.95% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -15045.50% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -41.52% |
Return on Equity (ttm) | -102.94% |
Income Statement
Revenue (ttm) | 1.59M EUR |
Revenue Per Share (ttm) | 0.04 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 1.07M EUR |
EBITDA | -232859008 EUR |
Net Income Avi to Common (ttm) | -228516992 EUR |
Diluted EPS (ttm) | -4.34 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 373.4M EUR |
Total Cash Per Share (mrq) | 8.64 EUR |
Total Debt (mrq) | 41.29M EUR |
Total Debt/Equity (mrq) | 17.25 EUR |
Current Ratio (mrq) | 8.818 |
Book Value Per Share (mrq) | 5.544 |
Cash Flow Statement
Operating Cash Flow (ttm) | -17961000 EUR |
Levered Free Cash Flow (ttm) | -97122752 EUR |
Profile of IGM Biosciences, Inc.
Country | Germany |
State | CA |
City | Mountain View |
Address | 325 East Middlefield Road |
ZIP | 94043 |
Phone | (650) 965-7873 |
Website | https://igmbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 280 |
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Q&A For IGM Biosciences, Inc. Stock
What is a current 1K0.F stock price?
IGM Biosciences, Inc. 1K0.F stock price today per share is 6.15 EUR.
How to purchase IGM Biosciences, Inc. stock?
You can buy 1K0.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for IGM Biosciences, Inc.?
The stock symbol or ticker of IGM Biosciences, Inc. is 1K0.F.
Which industry does the IGM Biosciences, Inc. company belong to?
The IGM Biosciences, Inc. industry is Biotechnology.
How many shares does IGM Biosciences, Inc. have in circulation?
The max supply of IGM Biosciences, Inc. shares is 65.17M.
What is IGM Biosciences, Inc. Price to Earnings Ratio (PE Ratio)?
IGM Biosciences, Inc. PE Ratio is now.
What was IGM Biosciences, Inc. earnings per share over the trailing 12 months (TTM)?
IGM Biosciences, Inc. EPS is -3.93 EUR over the trailing 12 months.
Which sector does the IGM Biosciences, Inc. company belong to?
The IGM Biosciences, Inc. sector is Healthcare.